JENNIFER CRIBB: Open Payments
NPI 1093047086 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,336 in 64 payments from 22 companies in 2025. Trend: 2023 $1,258 · 2024 $1,631 · 2025 $1,336
Food & beverage: $1,336
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $220 |
| PFIZER INC. | 11 | $211 |
| Lilly USA, LLC | 5 | $168 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $99 |
| Astellas Pharma US Inc | 4 | $81 |
| Novo Nordisk Inc | 4 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| ABBVIE INC. | 3 | $67 |
| Medtronic, Inc. | 1 | $33 |
Products named: JARDIANCE, NURTEC ODT, TRELEGY ELLIPTA, REXULTI, Veozah, SHINGRIX, CAPLYTA, UBRELVY.
Industry payments across NV — which companies pay providers there.
